Meiji : Notice concerning Application for Marketing Authorization of KD-370, Combination Vaccine for Pertussis, Diphteria, Tetanus, Inactivated Polio and Hib

April 25, 2022

Name of Company: Meiji Holdings Co., Ltd.

Name of Representative: Kazuo Kawamura, CEO, President and Representative Director

Code Number: 2269, Prime Market, Tokyo Stock Exchange

Notice concerning Application for Marketing Authorization of KD-370, Combination Vaccine for Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib

Meiji Holdings Co., Ltd. announced that its subsidiary KM Biologics Co., Ltd. submitted marketing authorization application of combination vaccine KD-370 to the Ministry of Health, Labour and Welfare (MHLW) today. KD-370 is a combination vaccine for pertussis, diphtheria, tetanus, acute poliomyelitis (polio) and Haemophilus influenzae type b (Hib).

KM Biologics has developed KD-370 in response to the MHLW's request from 2013 to develop vaccines with high priority. When KD-370 becomes available it is expected to reduce the number of routine vaccination shots for infants, thus reducing the burden on infants and their guardians.

The impact of this matter on consolidated earnings forecasts for the fiscal year ending March 31, 2023 is expected to be minor.

#####

Disclaimer: This English translation is prepared for the readers' convenience. When there are any discrepancies between the original Japanese version and English translation version, the original Japanese version always prevails.